Neurology Specific Literature Search   
 
[home][thesaurus]
    

Enter your terms
above and click
the 'Search' button.
Showing articles 0 to 50 of 423 Next >>

Filter Applied: Parkinson disease (Click to remove)

Non-Alzheimers Dementia 2 Lewy Body Dementias
Lancet 386:1683-1697, Walker, Z.,et al, 2015

Movement Disorders Emergencies Part 1
, Robottom, B.J., et al, 2011

Dystonia
NEJM 355:818-829, Tarsy,D. &Simon,D.K., 2006

Stalevo for Parkinson's Disease
The Medical Letter 46:39, , 2004

Comtan (Entacapone) The Treatment of Parkinson's Disease, Questions & Answers
APDA Ed Suppl #15, Watts,R.L., 2001

The Evolution of Diagnosis in Early Parkinson Disease
ArchNeurol 57:369-372, Jankovic,J.,et al, 2000

What is the Accuracy of the Clinical Diagnosis of Multiple System Atrophy
Arch Neurol 54:937-944, Litvan,I.,et al, 1997

Lewy Body Disease and Dementia
Arch Int Med 156:487-493, Kalra,S.,et al, 1996

Diffuse Lewy Body Disease:Clinical Features in Nine Cases without Coexistent Alzheimer's Disease
JNNP 60:531-538, Hely,M.A.,et al, 1996

Neuroleptic Drug Exposure and Treatment of Parkinsonism in the Elderly:A Case-Control Study
Am J Med 99:48-54, Avorn,J.,et al, 1995

A Clinicopathologic Study of 100 Cases of Parkinson's Disease
Arch Neurol 50:140-148, Hughes,A.J.,et al, 1993

Neurological and Neuropsychiatric Spectrum of Wilson's Disease:A Prospective Study of 45 Cases
J Neurol 238:281-287, Oder,W.,et al, 1991

Association of Coffee Consumption and Prediagnostic Caffeine Metabolites with Incident Parkinson Disease in a Population-Based Cohort
Neurol 102:e209201, Zhao,Y.,et al, 2024

Trial of Globus Pallidus Focused Ultrasound Ablation in Parkinsons Disease
NEJM 388:683-693, 759, Krishna,V.,et al, 2023

Complete Evaluation of Dementia: PET and MRI Correlation and Diagnosis for the Neuroradiologist
AJNR 42:998-1007, Oldan, J.D.,et al, 2021

Changing Gears - DBS for Dopaminergic Desensitization in Parkinsons Disease?
Ann Neurol 90:699-710, Weiss, D.,et al, 2021

Diagnosis and Treatment of Parkinson Disease
JAMA 323:548-560, Armstrong, M.J. & Okun, M.S., 2020

Personalized iPSC-Derived Dopamine Progenitor Cells for Parkinsons Disease
NEJM 382:1926-1932, Schweitzer, J.S.,et al, 2020

Deep Brain Stimulation in Early-Stage Parkinson Disease
Neurol 95:e393-e401,e431, Hacker, M.L.,et al, 2020

Non-Motor Symptoms in Parkinsons Disease are Reduced by Nabilone
Ann Neurol 88:712-722, Peball, M.,et al, 2020

When to Start Levodopa Therapy for Parkinsons Disease
NEJM 380:389-390, Bressman, S. & Saunders-Pullman, R., 2019

Placebo-Controlled, Randomized, Double-Blind Study of IncobotulinumtoxinA for Sialorrhea
Neurol 92:e1982-e1991, Jost, W.H.,et al, 2019

The Laser Shoes
Neurol 90:e164-e171, Barthel, C.,et al, 2018

National Randomized Controlled Trial of Virtual House Calls for Parkinson Disease
Neurol 89:1152-1161,1103, Beck, C.A.,et al, 2017

Management of Parkinson Disease in 2017
JAMA 318:791-792, Okun, M.S.,et al, 2017

Safety and Efficacy of Focused Ultrasound Thalamotomy for Patients with Medication-Refractory, Tremor-Dominant Parkinson Disease
JAMA Neurol 74:1412-1418, Bond, A.E.,et al, 2017

Restless Legs Syndrome Associated with Major Diseases
Neurol 86:1336-1343, Trenkwalder, C.,et al, 2016

Distinguishing Neuroimaging Features in Patients Presenting with Visual Hallucinations
AJNR 37:774-781, Winton-Brown, T.T.,et al, 2016

Withdrawing Amantadine in Dyskinetic Patients with Parkinson Disease
Neurol 82:300-307, Ory-Magne, F.,et al, 2014

Tremor
JAMA 311:948-954, Elias, W.J. & Shah, B.B., 2014

Long-Term Safety and Tolerability of ProSavin, a Lentiviral Vector-Based Gene Therapy for Parkinsons Disease: A Dose Escalation, Open-Label, Phase 1/2 Trial
Lancet 383:1138-1146,1107, Palfi, S.,et al, 2014

Systematic Review: Efficacy and Safety of Medical Marijuana in Selected Neurologic Disorders
Neurol 82:1556-1563, Koppel, B.S.,et al, 2014

Long-Term Effectivenss of Dopamine Agonists and Monoamine Oxidase B Inhibitors Compared with Levodopa as Initial Treatment for Parkinsons Disease (PD MED): A Large, Open-Label, Pragmatic Randomised Trial
Lancet 383: Doi: 10.1016/S0140-6736, PD MED Collaborative Group, 2014

Palliative Care and Neurology
Neurol 83:561-567, Boersma, I.,et al, 2014

Deep-Brain Stimulation - Entering the Era of Human Neural-Network Modulation
NEJM 371:1369-1373, Okun, M.S., 2014

Restless Genital Syndrome in Parkinson Disease
JAMA Neurol 71:1559-1561, Aquino, C.C.,et al, 2014

Degenerative Diseases of the Nervous System, Parkinson Disease
Adams & Victors Principles of Neurology, Chp 39, pg 1082, Ropper, A.H.,et al, 2014

Clinical Features of Dopamine Agonist Withdrawal Syndrome in a Movement Disorders Clinic
JNNP 84:130-135, Pondal, M.,et al, 2013

Neurostimulation for Parkinsons Disease with Early Motor Complications
NEJM 368:610-622, Rau, W.,et al, 2013

Randomized Controlled Clinical Trial of "Virtual House Calls" for Parkinson Disease
JAMA Neurol 70:565-570, Dorsey, E.R.,et al, 2013

Tai Chi and Postural Stability in Patients with Parkinsons Disease
NEJM 366:511-519, Li,F.,et al, 2012

Caffeine for Treatment of Parkinson Disease
Neurol 79:651-658, Postuma, R.B.,et al, 2012

Deep-Brain Stimulation for Parkinsons Disease
NEJM 367:1529-1538, Okon, M.S., 2012

Use of Ibuprofen and Risk of Parkinson Disease
Neurol 76:863-869, Gao,X.,et al, 2011

Deep Brain Stimulation
JAMA 305:732, Pluta,R.,et al, 2011

Deep Brain Stimulation for Parkinson Disease: An Expert Consensus and Review of Key Issues
Arch Neurol 68:165-171, Bronstein,J.M.,et al, 2011

Patterns and Trends in Antipsychotic Prescribing for Parkinson Disease Psychosis
Arch Neurol 68:899-904, Weintraub, D.,et al, 2011

Extended-Release Pramipexole in Advanced Parkinson Disease
Neurol 77:767-774, Schapira, A.H.V.,et al, 2011

Diagnosis and Treatment of Psychogenic Parkinsonism
JNNP 82:1300-1303, Jankovic, J., 2011



Showing articles 0 to 50 of 423 Next >>